Mark S. Gelder MD - 13 Mar 2023 Form 4 Insider Report for Onconova Therapeutics, Inc. (TRAW)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: TRAW
Reported as of: 13 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Mar 2023, 18:46:02 UTC
Prior SEC filing: 08 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark Guerin, Attorney-in-Fact

Key filing fact

Mark S. Gelder MD filed Form 4 for Onconova Therapeutics, Inc. (TRAW) on 14 Mar 2023.

Key facts

This page summarizes Mark S. Gelder MD's Form 4 filing for Onconova Therapeutics, Inc. (TRAW).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Mar 2023, 18:46.

Change

Previous filing in this sequence was filed on 08 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONTX transaction Derivative

Stock Option (right to purchase)

Award

Transaction value: $0
Shares: +62,000
Change %
Price: $0.000000
Shares after: 62,000
Date: 13 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,000
Exercise price: $0.7300
Footnotes: F1

ONTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +20,667
Change %
Price: $0.000000
Shares after: 20,667
Date: 13 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,667
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

Footnote F2

Each restricted stock unit is convertible into one share of common stock.

Footnote F3

These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary